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Abstract
Objective
To evaluate whether amyloid-related imaging abnormalities with edema/eﬀusion (ARIA-E)
observed in bapineuzumab clinical trials was associated with speciﬁc biomarker patterns.
Methods
Bapineuzumab, an anti-β-amyloid monoclonal antibody, was evaluated in patients with mild to
moderate Alzheimer disease. Amyloid PET imaging, CSF biomarkers, or volumetric MRI
(vMRI) were assessed.
Results
A total of 1,512 participants underwent one or more biomarker assessments; 154 developed
incident ARIA-E. No diﬀerences were observed at baseline between ARIA-E and non-ARIA-E
participants in brain amyloid burden by PET, the majority of vMRI measures, or CSF bio-
markers, with the exception of lower baseline CSF Aβ42 in APOE e4 noncarrier ARIA-E vs non-
ARIA-E groups (bapineuzumab non-ARIA-E p = 0.027; placebo non-ARIA-E p = 0.012). At
week 71, bapineuzumab-treated participants with ARIA-E vs non-ARIA-E showed greater
reduction in brain amyloid PET, greater reductions in CSF phosphorylated tau (p-tau) (all
comparisons p < 0.01), and total tau (t-tau) (all comparisons p < 0.025), and greater hippo-
campal volume reduction and ventricular enlargement (all p < 0.05). Greater reduction in CSF
Aβ40 concentrations was observed for ARIA-E versus both non-ARIA-E groups
(bapineuzumab/placebo non-ARIA-E p = 0.015/0.049). No group diﬀerences were observed at
week 71 for changes in whole brain volume or CSF Aβ42.
Conclusions
Baseline biomarkers largely do not predict risk for developing ARIA-E. ARIA-E was associated
with signiﬁcant longitudinal changes in several biomarkers, with larger reductions in amyloid
PET and CSF p-tau and t-tau concentrations, and paradoxically greater hippocampal volume
reduction and ventricular enlargement, suggesting that ARIA-E in bapineuzumab-treated cases
may be related to increased Aβ eﬄux from the brain and aﬀecting downstream pathogenic
processes.
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An urgent international priority is the search for eﬀective
therapies for Alzheimer disease (AD).1,2 Major eﬀorts have
been directed at developing disease-modifying therapies tar-
geting β-amyloid (Aβ) aggregation and toxicity,3 believed to
initiate the cascade of events that lead to the disease.4 The
search so far has been unsuccessful; but insights from these
eﬀorts have helped reﬁne clinical trial methodology.5
Observations of MRI abnormalities in trials evaluating anti-
amyloid therapies for AD led to the use of the term amyloid-
related imaging abnormalities (ARIA)6 to describe a spectrum
of MRI ﬁndings. ARIA-E refers to areas of hyperintensity on
ﬂuid-attenuation inversion recovery (FLAIR) MRI reﬂecting
parenchymal edema or sulcal eﬀusion and ARIA-H refers to
areas of hypointensity on T2*-weighted gradient echo MRI
reﬂecting iron deposits in the form of hemosiderin. Animal
models indicate that anti-Aβ treatment removes vascular
amyloid, resulting in leakage of blood, ﬂuid imbalances, and
microhemorrhages/hemosiderin deposition.7
Bapineuzumab, an anti-Aβ monoclonal antibody, was evalu-
ated in phase 3 trials for the treatment of mild to moderate
AD.8–11
Centralized reviews of bapineuzumab MRI scans have shown
increased risk for developing ARIA-E with increasing number
of APOE e4 alleles, with increasing bapineuzumab dose,12 and
in bapineuzumab-treated carriers who had microhemorrhages
at baseline.13 The reported ARIA-E cases were largely
asymptomatic and typically resolved without intervention
within 90 days of detection.12–14 Similar patterns were ob-
served in trials with other anti-Aβ monoclonal antibodies,
gantenerumab,15 and aducanumab.16
The objective of this study was to compare the CSF and
imaging biomarker pattern between participants who de-
veloped ARIA-E and those who did not.
Methods
Patients
Enrollment and randomization for the bapineuzumab phase 3
Pittsburgh compound B (PiB) PET, CSF, and volumetric
MRI (vMRI) substudies were the same as for the main studies
described previously.8 In brief, eligible patients were aged
50–88 years inclusive, met clinical criteria for probable AD,17
had a Mini-Mental State Examination (MMSE)18 score of
16–26, and had a modiﬁed Hachinski Ischemic Score ≤4.19 A
key exclusion was evidence of clinically signiﬁcant neurologic
disease other than AD.
In the APOE e4 carrier study, 1,121 participants were ran-
domized in a ratio of 3:2 bapineuzumab 0.5 mg/kg to placebo.
In the noncarrier study, 1,331 participants were randomized
in a ratio of 1:1:1:2 bapineuzumab 0.5 mg/kg:1 mg/kg:2
mg/kg to placebo. The 2 mg/kg dose was discontinued early
in the trial owing to safety events (symptomatic ARIA) but
participants randomized to that dose were included in these
analyses. Stratiﬁcation factors used in randomization included
baseline MMSE total score (low 16 to 21 vs high 22 to 26);
current cholinesterase inhibitor or memantine use; and, in the
carrier study, APOE e4 copy number (1 vs 2). Study drug was
administered as a 1-hour IV infusion every 13 weeks during
the 18-month study.
The primary objective of the phase 3 studies was to evaluate
the eﬃcacy of bapineuzumab compared with placebo by
measuring the change from baseline to week 78 in cognitive
and functional endpoints. Key secondary objectives were to
evaluate the eﬀect of bapineuzumab on change from baseline
to week 71 in brain Aβ burden by 11C-PiB PET, change in
CSF phosphorylated tau (p-tau), and global brain volume
reduction in subsets. Exploratory objectives included pooled
analyses using all analyzable patients from both studies on the
eﬀect of bapineuzumab on 11C-PiB PET, CSF p-tau, and
global/regional vMRI changes. Biomarker sample sizes for
each of the studies (carriers and noncarriers) were reported
previously8–10 and are provided in ﬁgure e-1 (links.lww.com/
WNL/A213).
11C-PiB PET scans were obtained at baseline, week 45, and
week 71. PET imaging was conducted at 14 US academic PET
centers. Camera-speciﬁc acquisition, emission correction, and
reconstruction settings were adopted from the Alzheimer’s
Disease Neuroimaging Initiative.20,21 Image analyses were
performed by a core imaging laboratory for 11C-PiB PET
signal (standard uptake value ratio [SUVr]) in a global
composite average (GCA) comprising 5 cortical brain regions
known to accumulate amyloid in AD (anterior cingulate,
frontal cortex, lateral temporal cortex, parietal cortex, and
posterior cingulate/precuneus) relative to a reference region
(cerebellar gray matter).9 Three-dimensional T1-weighted
MRI scans were obtained at screening and weeks 19, 45, and
Glossary
Aβ = β-amyloid; AD = Alzheimer disease; ANCOVA = analysis of covariance; ARIA = amyloid-related imaging abnormalities;
ARIA-E = amyloid-related imaging abnormalities–edema or eﬀusion; BBSI = brain boundary shift integral; CI = conﬁdence
interval; FLAIR = ﬂuid-attenuation inversion recovery; GCA = global composite average;HBSI = hippocampal boundary shift
integral;HCV = hippocampal volume; LS = least square;MMSE =Mini-Mental State Examination; p-tau = phosphorylated tau;
PiB = Pittsburgh compound B; SUVr = standard uptake value ratio; t-tau = total tau;VBSI = ventricular boundary shift integral;
vMRI = volumetric MRI; VV = ventricular volume; WBV = whole brain volume.
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71 for brain vMRI. Changes were measured in whole brain
volume (WBV) by the brain boundary shift integral (BBSI),
ventricular volume (VV) by the ventricular boundary shift
integral (VBSI), and total hippocampal volume (HCV) by
hippocampal boundary shift integral (HBSI). Methods for
image acquisition, processing, and quantitation were pre-
viously described.10 CSF samples were collected at baseline
and week 71, and Aβ40, Aβ42, p-tau, and total tau (t-tau)
concentrations determined. Methods for sample collection,
bioanalysis, and quantitation were described in Blennow
et al.22
Determination of ARIA-E FLAIR MRI brain images were
obtained at the screening visit; weeks 6, 19, 32, 45, 58, and 71;
and additionally as necessary per physician’s discretion for
safety monitoring. All FLAIR MRI brain images were read
retrospectively at the central imaging core laboratory by 2
readers reaching a consensus. ARIA-E was deﬁned as evidence
of parenchymal or sulcal hyperintensity.8,13
Statistical analysis
Participants who received at least part of one infusion and had
at least one satisfactory retrospective safety MRI read were
categorized into 3 groups: bapineuzumab-treated participants
who developed ARIA-E, bapineuzumab-treated participants
who did not develop ARIA-E (bapineuzumab non-ARIA-E),
and placebo-treated participants who did not develop ARIA-E
(placebo non-ARIA-E). All 3 groups included only patients
who had no ARIA-E at baseline. Eight patients in the placebo
arm developed incident ARIA-E but were excluded from these
analyses since none had 11C-PiB PET data, only 2 had CSF
data, and 3 had vMRI data. Since all ARIA-E participants
included in these analyses were bapineuzumab-treated, this
group is referred to as ARIA-E participants for simplicity.
Baseline levels of 11C-PiB PET GCA SUVr, CSF p-tau, t-tau,
Aβ42, Aβ40, WBV, VV, and HCV were analyzed separately
using a series of analysis of covariance (ANCOVA) models.
For each biomarker, the analysis was performed in patients
who were in 1 of the 3 groups deﬁned above and had
a baseline measurement of the corresponding biomarker. The
response variable was the biomarker at baseline. The dis-
tributions of CSF biomarkers were highly skewed. These
biomarkers were log-transformed before the statistical anal-
yses. The main factor of interest in the model was group. Age,
sex, and number of APOE e4 alleles were included in all
models as covariates. Number of small hemosiderin deposits
(<10 mm) at baseline, number of large hemosiderin deposits
(≥10 mm) at baseline, and white matter hyperintensity
score23 at baseline were also included in the models for WBV,
VV, and HCV as covariates. The diﬀerences in baseline bio-
markers among the 3 groups were assessed by t tests con-
trasting the least square (LS) mean estimates of the 3 groups.
Change from baseline in 11C-PiB PET GCA SUVr, and BBSI,
VBSI, and HBSI, were analyzed using mixed models for re-
peated measures. For each biomarker, the analysis was
performed in patients who were in one of the 3 groups deﬁned
above, had a baseline measure of the biomarker, and had
a postbaseline measure of the biomarker collected after the
onset of ﬁrst ARIA-E. The response variable was the change in
biomarker at all postbaseline visits. All models included the
following ﬁxed eﬀects: visit, group, visit by group interaction,
age, sex, number of APOE e4 alleles, and dose of bapineu-
zumab (0.5, 1, or 2 mg). The model for 11C-PiB PET GCA
SUVr also included baseline GCA SUVr as a ﬁxed eﬀect. The
models for BBSI, VBSI, and HBSI also included numbers of
small (<10 mm) or large (≥10 mm) hemosiderin deposits at
baseline and white matter hyperintensity score at baseline as
ﬁxed eﬀects. The correlations among repeated measures were
modeled with an unstructured covariance matrix. The diﬀer-
ences in changes in biomarkers among the 3 groups were
assessed by t tests contrasting the LS mean estimates of the 3
groups at the last visit available for the biomarker.
CSF samples were collected at baseline and at only 1 post-
baseline visit. Changes from baseline in CSF p-tau, t-tau, Aβ42,
and Aβ40 were analyzed using ANCOVA models in partic-
ipants who were in one of the 3 groups deﬁned above, had
a baseline CSF measure, and had a postbaseline CSF measure
collected after day 365 or the onset of the ﬁrst ARIA-E,
whichever was later. The response variables were the changes
from baseline in log-transformed CSF biomarkers. The main
factor of interest was group. Age, sex, number of APOE e4
alleles, dose of bapineuzumab, and corresponding CSF bio-
marker (in log scale) at baseline were included in the models
as covariates. The diﬀerences in changes in these biomarkers
were assessed by t tests contrasting the LS mean estimates of
the 3 groups.
All analyses were performed in noncarrier and carrier studies
separately as well as pooled. All analyses were performed
using SAS 9.2 (sas.com).
Standard protocol approvals, registrations,
and patient consents
Bapineuzumab noncarrier and carrier studies were registered
on ClinicalTrials.gov (NCT00575055 and NCT00574132)
and EudraCT (2009-012748-17). Prior to participation, each
site’s institutional review board or ethics committee approved
the study, and each participant (or legally authorized repre-
sentative) gave written informed consent.
Results
In the bapineuzumab APOE e4 noncarrier and carrier studies,
a total of 1,512 participants participated in one or more of the
biomarker substudies. Of these, 909 were in the bapineuzu-
mab group (154 with ARIA-E and 755 non-ARIA-E), while
595 were in the placebo group (non-ARIA-E) (ﬁgure 1).
APOE e4 carrier frequency was higher in bapineuzumab
ARIA-E participants compared with bapineuzumab non-
ARIA-E participants (58% vs 46%; p = 0.0057; table). Further,
there was a higher proportion of APOE e4 homozygotes in
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bapineuzumab ARIA-E participants (26.0% vs 8.6%), but
no diﬀerences in age, sex, race, or baseline MMSE com-
pared to bapineuzumab or placebo non-ARIA-E partic-
ipants (table).
Comparing baseline brain PET amyloid signal (GCA SUVr)
between ARIA-E and non-ARIA-E groups, no diﬀerences
were observed for all participants with PiB PET data (p >
0.56; ﬁgure 2A), for those with baseline GCA SUVr >1.35
(p > 0.29; ﬁgure 2C), or between groups for individual study
comparisons (ﬁgures e-2, A and C, and e-3, A and C, links.
lww.com/WNL/A213). Bapineuzumab-treated participants
who developed ARIA-E showed greater reduction at week 71
in PiB PET signal compared with non-ARIA-E participants
(p < 0.0016; ﬁgure 2B). A similar pattern was observed for
participants with baseline GCA SUVr >1.35 (p < 0.0023;
ﬁgure 2D) and for APOE e4 carriers (ﬁgure e-2, B and D).
For the APOE e4 noncarriers, a numerically greater re-
duction in PiB PET signal was observed in ARIA-E partic-
ipants, but was not statistically signiﬁcant (ﬁgure e-3, B
and D).
No diﬀerences between ARIA-E and non-ARIA-E partic-
ipants were observed in the baseline WBV, VV, or HCV (p >
0.095; ﬁgure 3, A, C, and E) with the exception of greater VV
in ARIA-E vs placebo non-ARIA-E participants (p = 0.049;
ﬁgure 3C). No diﬀerences were observed between groups
for baseline WBV, VV, or HCV for individual study com-
parisons (ﬁgures e-4, A and C; e-5, A and C; and e-6, A and
C, links.lww.com/WNL/A213). Greater ventricular
Table Demographics and baseline characteristics
Bapineuzumab ARIA-E (n = 154) Bapineuzumab non-ARIA-E (n = 755) Placebo non-ARIA-E (n = 595)
Age, y, mean (SD) 71.2 (8.1) 72.1 (9.0) 71.3 (9.5)
Sex, n (% female) 66 (42.9) 359 (47.5) 267 (44.9)
Race, n (% white) 149 (96.8) 697 (92.3) 560 (94.1)
APOE «4, n (%) 90 (58.5) 349 (46.2) 286 (48.1)
Heterozygote «4, n (%) 50 (32.5) 284 (37.6) 214 (36.0)
Homozygote «4, n (%) 40 (26.0) 65 (8.6) 72 (12.1)
Baseline MMSE total score, mean (SD) 20.9 (3.0) 21.1 (3.2) 21.1 (3.1)
Abbreviations: ARIA-E = amyloid-related imaging abnormalities–edema or effusion; MMSE = Mini-Mental State Examination.
Figure 1 Disposition of biomarker substudy participation by amyloid-related imaging abnormalities–edema or effusion
(ARIA-E) status
The number of participants enrolled
into the APOE e4 carrier and non-
carrier studies, the number of partic-
ipants who consented to one or more
of the biomarker substudies (amyloid
PET, CSF, or volumetric MRI), and
breakdown of biomarker study
participants by treatment and ARIA-E
status.
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enlargement (VBSI) and hippocampal volume reduction
(HBSI) were observed at week 71 in ARIA-E vs non-ARIA-E
participants (all comparisons p < 0.001; ﬁgure 3, D and F).
Similarly, greater VBSI and HBSI were observed at week 71
in ARIA-E vs non-ARIA-E participants for individual study
comparisons (ﬁgure e-5, B and D; e-6, B and D). No dif-
ferences were observed in whole brain volume reduction
(BBSI) at week 71 between ARIA-E and non-ARIA-E groups
(p > 0.58; ﬁgure 3B) or between groups for individual study
comparisons (ﬁgure e-4, B and D).
No diﬀerences in baseline CSF Aβ42, or Aβ40, p-tau, or t-tau
between groups were observed (all comparisons p > 0.089;
ﬁgure 4, A, C, E, and G) or for individual study comparisons
(ﬁgures e-7C; e-8, A and C; e-9, A and C; and e-10, A and C,
links.lww.com/WNL/A213), except for lower CSF Aβ42 in
APOE e4 noncarrier ARIA-E vs non-ARIA-E participants
(ﬁgure e-7A).
Greater reductions at week 71 in CSF p-tau and t-tau (all
comparisons p < 0.001; ﬁgure 4, F and H) were seen for
Figure 2 Brain amyloid PET burden at baseline and change over 71 weeks by amyloid-related imaging abnormalities–
edema or effusion (ARIA-E) status
Comparison of brain amyloid burden by Pittsburgh compound B (PiB) PET (global composite average [GCA] standard uptake value ratio [SUVr]) between
bapineuzumab (Bapi) ARIA-E vs Bapi or placebo (Pbo) non-ARIA-E groups in all participants with PiB PET data for (A) baseline values or (B) change from
baseline to week 71 values. Comparisons between groups in participants who were amyloid-positive at study entry by PiB PET (GCA SUVr >1.35) for
(C) baseline values or (D) change from baseline to week 71 values. Data plotted are least square (LS) means ± 1 standard error.
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Figure 3 Brain volumetric MRI at baseline and change over 71 weeks by amyloid-related imaging abnormalities–edema or
effusion (ARIA-E) status
Comparison of brain volumes between bapineuzumab (Bapi) ARIA-E vs Bapi or placebo (Pbo) non-ARIA-E groups for (A) baseline whole brain volumes (WBV),
(B) change from baseline to week 71 WBV by boundary shift integral (BBSI), (C) baseline ventricular volumes (VV), (D) change from baseline to week 71 VV by
ventricular boundary shift integral (VBSI), (E) baseline hippocampal volumes (HV), and (F) change frombaseline to week 71HV by hippocampal boundary shift
integral (HBSI). Data plotted are least square (LS) means ± 1 standard error.
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ARIA-E vs non-ARIA-E participants and were similarly ob-
served between groups in individual study comparisons
(ﬁgures e-9, B and D, and e-10, B and D, links.lww.com/
WNL/A213). There was a greater reduction at week 71 in
CSF Aβ40 concentrations for ARIA-E vs non-ARIA-E
participants (p < 0.05; ﬁgure 4D) and in carrier (ﬁgure e-8,
D) but not for noncarrier comparisons (ﬁgure e-8, B). No
diﬀerences at week 71 were observed for CSF Aβ42 between
ARIA-E and non-ARIA-E participants (ﬁgure 4B) or for in-
dividual study comparisons (ﬁgure e-7, B and D).
Figure 4 CSF biomarkers at baseline and change over 71 weeks by amyloid-related imaging abnormalities–edema or
effusion (ARIA-E) status
Comparison of CSF biomarkers between
bapineuzumab (Bapi) ARIA-E vs Bapi or
placebo (Pbo) non-ARIA-E groups for (A)
baseline CSF Aβ42 concentration, (B) change
from baseline to week 71 CSF Aβ42 concen-
tration, (C) baseline CSF Aβ40 concentration,
(D) change from baseline to week 71 CSF Aβ40
concentration, (E) baseline CSF phosphory-
lated tau (p-tau) concentration, (F) change
from baseline to week 71 CSF p-tau concen-
trations, (G) baseline CSF total tau (t-tau)
concentrations, and (H) change from baseline
to week 71 CSF t-tau concentrations. Data
plotted are least square (LS) means ± 1
standard error.
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Discussion
ARIA are imaging-deﬁned phenomena observed with anti-
amyloid therapies for AD; ARIA-E refers to changes seen on
FLAIR MRI that are thought to represent cerebral paren-
chymal edema and sulcal eﬀusions.6 ARIA-E may rarely occur
spontaneously but is much more frequent with therapies di-
rected against cerebral amyloid,6,24 especially with anti-
amyloid immunotherapy using antibodies directed against
aggregated/ﬁbrillar Aβ.8,12–16 ARIA are usually asymptomatic
and typically resolve within 3 months but importantly can be
dose-limiting for therapeutic trials.8,12,14 The present study
evaluated whether the occurrence of ARIA-E is associated
with speciﬁc biomarker patterns at baseline or longitudinally
in 2 phase 3 trials with bapineuzumab.8 The incidence of
ARIA-E (;10%) in the biomarker substudy participants was
similar to that in the parent trials.8
Generally, baseline biomarker status (brain amyloid burden
on PiB PET; brain, ventricular, and hippocampal volumes on
MRI; CSF p-tau, t-tau, Aβ40, and Aβ42) was not associated
with development of ARIA-E. However, APOE e4 noncarrier
participants who developed ARIA-E had lower baseline CSF
Aβ42 concentrations (and nonsigniﬁcant greater ventricular
volumes). Reduced CSF Aβ42 is a marker of AD pathology
and correlates, inversely, with cortical amyloid deposition
evaluated by amyloid PET.23,25,26 This APOE gene–dose-
dependent association is seen in elderly, but not in younger,
individuals, irrespective of clinical status, but is not present
when stratiﬁed for amyloid PET status,27 further supporting
that low CSF Aβ42 may be a more sensitive indicator of brain
amyloid positivity than amyloid PET.28,29 Indeed, baseline
amyloid PET was not found to be increased in the noncarriers
with ARIA-E. The lack of diﬀerence in baseline amyloid PET
between groups may also be due to the low numbers who
underwent PiB PET and that few had both PET and CSF
assessments, resulting in nonoverlapping analysis
populations.
A greater baseline ventricular volume was observed for ARIA-
E participants compared with the placebo non-ARIA-E
participants, a diﬀerence largely driven by the noncarrier
participants. The fact that bapineuzumab-treated participants
who developed ARIA-E did not have larger ventricles than
bapineuzumab-treated participants who did not develop
ARIA-E suggests that ventricular enlargement is not a speciﬁc
risk factor for ARIA-E.
In terms of longitudinal changes, bapineuzumab-treated par-
ticipants who developed ARIA-E had a reduction in amyloid
burden (PiB PET) compared to those who did not develop
ARIA-E.
Previous reports have suggested a relationship between brain
areas with ARIA-E and localized amyloid clearance.12,15
Although this study did not evaluate regional, localized asso-
ciations between ARIA-E and PiB PET changes, the reductions
in global SUVr over the 18-month study were clearly signiﬁcant
in the bapineuzumab-treated ARIA-E group despite relatively
small numbers in each group. In contrast, there was a lack of
change from baseline in the non-ARIA-E groups.
The ARIA-E participants also had a greater reduction in total
hippocampal volume (indexed by greater HBSI) and a sig-
niﬁcantly greater ventricular volume increase (indexed by
a greater VBSI) compared to both the bapineuzumab non-
ARIA-E and placebo non-ARIA-E groups. These changes
appeared early in the study: by week 19, the majority of the
volumetric diﬀerences between the ARIA-E and the non-
ARIA-E groups were already present. Diﬀerences were similar
in magnitude for brain volume changes (BBSI), though they
did not reach statistical signiﬁcance. One explanation for these
volumetric changes is that they are due to a greater removal of
amyloid plaques and the reduction in plaque-associated pa-
thology (e.g., inﬂammatory changes) in ARIA-E participants,
as suggested by the greater reduction in PiB PET signal. This
might be expected to reduce brain parenchymal volume and
cause an ex vacuo expansion of the ventricles. Thus, the in-
creased ventricular enlargement in ARIA-E participants
(VBSI diﬀerence of 2.9 mL [95% conﬁdence interval (CI)
1.7–4.2] compared with bapineuzumab non-ARIA-E partic-
ipants and 3.8 mL [95% CI 2.6–5.1] compared with placebo
non-ARIA-E) could have resulted from a change of as little as
;0.3–0.4% of total brain volume.
Another potential cause of volumetric change that must be
considered is an accelerated rate of neurodegeneration in
participants who experienced ARIA-E; several ﬁndings
counter this explanation, including a lack of diﬀerence in
clinical outcomes8 between ARIA-E and non-ARIA-E groups
and the greater reduction in CSF p-tau and t-tau in ARIA-E
participants. Although there were more APOE e4 homo-
zygotes among ARIA-E participants, volumetric diﬀerences
were similar when APOE e4 carriers and noncarriers were
examined separately.
Finally, it has been suggested that mobilization of β-amyloid
from plaques may result in its transient deposition in peri-
vascular spaces7; this in turn blocks perivascular ﬂow of in-
terstitial ﬂuid, leading to interstitial edema (ARIA-E) with
eventual resolution through drainage of the excess ﬂuid into
the lateral ventricles.30 While this may explain a proportion of
ventricular volume increase, it would not be pertinent for the
greater reduction in hippocampal volume.
The greater reductions in CSF p-tau and t-tau in ARIA-E
compared with non-ARIA-E groups may indicate that ARIA-
E, except for being an MRI ﬁnding, is a marker for better
treatment response (as also supported by the PET ﬁndings),
with reductions towards normalization of the downstream
biomarkers p-tau and t-tau.
The main limitation for this study was the small sample size
for most comparisons. There were only 154 ARIA-E cases in
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this sample and when evaluating by APOE e4 carrier status,
the sample becomes even smaller. A second limitation was
that the groups were categorized based on ARIA-E status and
treatment assignment without accounting for timing of the
event occurrence relative to the analyses of change over time.
Given the preliminary nature of this analysis, there were no
corrections for multiple comparisons and thus the p values are
considered nominal. A further limitation is that, due to the
small number of participants with all 3 biomarker assess-
ments, multivariate analyses were not feasible for the baseline
biomarker analyses. Finally, further studies need to be per-
formed in order to validate the ﬁndings from this study.
In this study, baseline biomarkers do not predict risk for de-
veloping ARIA-E, except perhaps in APOE e4 noncarriers
showing greater evidence of Aβ accumulation (lower CSFAβ42).
ARIA-E was associated with several signiﬁcant longitudinal
biomarker changes including reduction in amyloid deposition
and lower CSF markers of downstream neurodegeneration.
Somewhat paradoxically, ARIA-E also appeared to be associated
with early increases in ventricular volume and reductions in
hippocampal volume. These ﬁndings suggest that eﬄux of Aβ
from the brain parenchyma associated with ARIA-E might in-
ﬂuence downstream disease pathogenic processes and may shed
light on the mechanism of action of bapineuzumab.
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Study question
Is the observed occurrence of amyloid-related imaging ab-
normalities with edema/eﬀusion (ARIA-E) in clinical trials of
bapineuzumab associated with speciﬁc biomarker patterns?
Summary answer
Longitudinal changes in various biomarkers were associated
with incident ARIA-E.
What is known and what this paper adds
Incident ARIA-E has been reported in clinical trials of bapi-
neuzumab and is associated with the presence of APOE e4
alleles. This study elucidates the biomarkers associated with the
development of ARIA-E in patients receiving bapineuzumab.
Participants and setting
This study analyzed 1,504 patients with probable Alzheimer
disease who participated in phase 3 clinical trials of bapi-
neuzumab. They either did (n = 725) or did not (n = 779)
carry APOE e4 alleles.
Design, size, and duration
Phase 3 clinical trial data were retrospectively analyzed for
patients who received bapineuzumab (n = 909) or a placebo
(n = 595). These data included subsets with 11C-PiB PET
scans, which reﬂected β-amyloid (Aβ) levels; MRI scans,
which reﬂected global and regional brain volumes; and CSF
measurements of speciﬁc forms of tau and Aβ. The study
assessed longitudinal changes in these measurements as pre-
dictive biomarkers for the primary outcome.
Primary outcomes
The primary outcome was developing ARIA-E during the study.
Main results and the role of chance
There were 154 cases of incident ARIA-E in the bapineuzumab-
treated group. Compared to bapineuzumab-treated participants
without ARIA-E, those with ARIA-E were more likely to carry
APOE e4 alleles (46% vs 58%; p = 0.0057). In week 71, com-
pared to placebo- and bapineuzumab-treated participants without
ARIA-E, participants with ARIA-E had greater reduction in brain
amyloid burden by 11C-PiB PET (p = 0.0016), greater ventricular
enlargement and hippocampal volume reduction (p < 0.001 for
both), and greater reductions in CSF levels of phosphorylated tau
(p < 0.001), total tau (p < 0.001), and Aβ40 (p < 0.05).
Bias, confounding, and other reasons
for caution
The study included only 154 participants with ARIA-E. The
study did not account for when the participants developed
ARIA-E. Lack of complete biomarker data for all participants
limited the analyses.
Generalizability to other populations
Data from placebo-treated participants with ARIA-E were
excluded. This may limit generalizability to patients who
spontaneously develop ARIA-E.
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